๐Ÿงช Heading to #AACR2025 and interested in advancing antibody discovery technologies?

Join us at ๐—ฃ๐—ผ๐˜€๐˜๐—ฒ๐—ฟ ๐—Ÿ๐—•๐Ÿฌ๐Ÿฌ๐Ÿฏ on ๐—ฆ๐˜‚๐—ป๐—ฑ๐—ฎ๐˜† ๐—”๐—ฝ๐—ฟ๐—ถ๐—น ๐Ÿฎ๐Ÿณ during the afternoon poster session where we will present our most recent data from MImAbs SAS.

๐Ÿ“Œ Highlight: We employed the ๐—•๐—ฒ๐—ฎ๐—ฐ๐—ผ๐—ปยฎ ๐˜€๐—ถ๐—ป๐—ด๐—น๐—ฒ-๐—• ๐—ฐ๐—ฒ๐—น๐—น ๐˜€๐—ฐ๐—ฟ๐—ฒ๐—ฒ๐—ป๐—ถ๐—ป๐—ด ๐—ฝ๐—น๐—ฎ๐˜๐—ณ๐—ผ๐—ฟ๐—บ to isolate novel monoclonal antibodies with ๐—ต๐—ถ๐—ด๐—ต ๐˜€๐—ฝ๐—ฒ๐—ฐ๐—ถ๐—ณ๐—ถ๐—ฐ๐—ถ๐˜๐˜† toward cancer-associated targets. Our approach enables rapid functional screening at the single-cell level, accelerating the path from B cell to candidate.

If you’re interested in learning more or discussing potential collaborations, feel free to ๐—ฟ๐—ฒ๐—ฎ๐—ฐ๐—ต ๐—ผ๐˜‚๐˜ ๐˜๐—ผ ๐˜‚๐˜€ ๐˜๐—ผ ๐˜€๐—ฐ๐—ต๐—ฒ๐—ฑ๐˜‚๐—น๐—ฒ ๐—ฎ ๐—บ๐—ฒ๐—ฒ๐˜๐—ถ๐—ป๐—ด ๐—ฑ๐˜‚๐—ฟ๐—ถ๐—ป๐—ด ๐˜๐—ต๐—ฒ ๐—ฐ๐—ผ๐—ป๐—ณ๐—ฒ๐—ฟ๐—ฒ๐—ป๐—ฐ๐—ฒ weโ€™d be happy to connect!

#AACR2025 #AntibodyDiscovery #CancerResearch #SingleBCellScreening #BeaconPlatform #Bruker #ImmunoOncology #TranslationalResearch #MImAbs

Do you have any project? Or question?

Contact MimAbs to discuss your project, our team will support you in the scientific study and strategic development planning of your project.

Contact an expert